bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Physicians
 Resources from HONselect
Drug Company Reps Don't Tell Docs Enough About Side Effects: Survey
Many U.S., Canadian and French physicians prescribed the promoted meds anyway

By Robert Preidt

WEDNESDAY, April 10 (HealthDay News) -- Drug company salespeople provide family doctors with little or no information about the harmful effects of medicines they are promoting, a new study says.

Despite this lack of knowledge, doctors are likely to start prescribing these drugs after visits from company representatives, according to the findings from questionnaires completed by American, Canadian and French doctors.

The study revealed that salespeople failed to provide any information about common or serious side effects or warn doctors about types of patients who should not use the medicine in 59 percent of the promotions.

"Laws in all three countries require sales representatives to provide information on harm as well as benefits," lead author Barbara Mintzes, of the University of British Columbia, said in a university news release. "But no one is monitoring these visits and there are next to no sanctions for misleading or inaccurate promotion."

Serious risks were mentioned in only 6 percent of the promotions, even though 57 percent of the medicines involved in these visits came with U.S. Food and Drug Administration "black box" or Health Canada boxed warnings, which are the strongest types of drug warnings in the two countries.

"We are very concerned that doctors and patients are left in the dark and patient safety may be compromised," Mintzes said.

Doctors in France were more likely to be told about the potential harmful effects of drugs during promotional visits than their counterparts in Canada and the United States. This may be due to tighter regulations for promotion of medicines in France, the researchers said.

The study was published online April 10 in the Journal of General Internal Medicine.

More information

The U.S. Food and Drug Administration has more about drug safety issues.

SOURCE: University of British Columbia, news release, April 10, 2013

Health News Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=675247

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Data Collection
Specialty Chemicals and Products
Physicians
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact